Classifying cancers based on T cell infiltration and PD-L1
By M. Teng, S. Ngiow, Antoni Ribas, M. Smyth. Cancer Research, 2015
1,297 citations recorded by the source corpus.
Cancer immunotherapy may become a major treatment backbone in many cancers over the next decade. There are numerous immune cell types found in cancers and many components of an immune reaction to cancer. Thus the tumor has many strategies to evade an immune response. It has been proposed that four different types of tumor microenvironment exist based on the presence or absence of tumor infiltrating lymphocytes and programmed death-ligand 1 (PD-L1) expression. We review this stratification and the latest in a series of results that shed light on new approaches for rationally designing ideal combination cancer therapies based on tumor immunology.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/39495347f41d8343dbd1585215b609b302c2c157
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
Citations in the corpus
- Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors (2018, background): “Recently, a tumor immune microenvironment model which consists of TIL status (presence or absence) and PD-L1 expression status (positive or negative) is established for immunotherapy prediction [46].”
- A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging (2018, neutral): “Several studies have shown increased tumor infiltrating lymphocytes (TILs) in TNBC compared to other breast cancers and correlations between specific immune subsets and prognosis (Andre et al., 2013; Denkert et al., 2010; Disis and Stanton, 2015; Teng et al., 2015), leading to clinical studies of se”
- From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review) (2018, neutral): “It has been proposed that four different types of tumor microenvironment exist based on the presence or absence of TILs and PD‑L1 expression (34).”
- Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma (2016, methodology): “To further explore whether TP53 or KRAS mutation would influence the TME, we analyzed the correlation between TP53 or KRAS mutation and TME immune types classified based on PD-L1 and CD8A expression as previously described (28, 29).”
- The Principles of Engineering Immune Cells to Treat Cancer (2017, background): “However, since every cancer is different, it is possible that particular facets will be more critical for each target disease (Teng et al., 2015).”
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. (2019, neutral): “These findings support the hypothesis that patients with low TILs will most likely not respond to single-agent immune checkpoint inhibitors, and require alternative treatment strategies (Teng et al., 2015).”